All In Biotech

Drug Trial Radar · NCT06501651

Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy

A Prospective, Randomized, Controlled, Multicenter Study of Sacubitril/Valsartan in the Treatment of Patients With Mild to Moderate Essential Hypertension and Type 2 Diabetic Nephropathy: The Hyper-Save Study

Last checked: Nov 20, 2026Latest source record: Jul 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 297 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

297

Planned (sponsor's estimate)

Start

Aug 1, 2024

Primary completion

Apr 10, 2025

Study completion Apr 10, 2025

Sponsor

Lead sponsor
Sichuan Academy of Medical SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Second Affiliated Hospital of Chongqing Medical University; Nanchong Central Hospital; The People's Hospital of Leshan; The Affiliated Traditional Chinese Medicine Hospital Of Southwest Medical University; Chengdu First People's Hospital; Mianyang People's Hospital; Guang'an people's hospital of Sichuan province; Meishan Traditional Chinese Medicine Hospital; Qijiang District People's Hospital; Meishan People's Hospital; The First People's Hospital of Guangyuan; Dazhou Central Hospital
First posted
Jul 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to compare the efficacy and safety of Sacubitril/Valsartan versus Valsartan in patients with essential hypertension and type 2 diabetic nephropathy over a 12-week treatment period, including two treatment groups, with a total of 297 eligible subjects randomly assigned in a 2:1 ratio to either the experimental group or the control group.Subjects will participate in the study through two phases: the screening period and the follow-up period.The primary outcome measure is the change in systolic blood pressure from baseline after 12 weeks of treatment.

Conditions

  • Essential Hypertension
  • Type 2 Diabetes
  • Nephropathy

Interventions

  • Sacubitril/ValsartanDrug

    Sacubitril/Valsartan is a novel antihypertensive medication composed of an angiotensin II receptor blocker (ARB) Valsartan and a neprilysin inhibitor Sacubitril in a 1:1 molar co-crystal form. Sacubitril is a prodrug that, once ingested, is metabolized by esterases into its active form, which inhibits neprilysin activity. Neprilysin has various substrates, including natriuretic peptides and angiotensin II (Ang II). By inhibiting neprilysin, the levels of natriuretic peptides that have antihypertensive and organ-protective effects are increased. The other component, Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing additional antihypertensive and organ-protective effects. The co-crystal structure ensures that Sacubitril and Valsartan have similar absorption and elimination rates, thereby synchronizing their pharmacological effects.

  • ValsartanDrug

    Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing both antihypertensive and organ-protective effects.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction in 24-hour ambulatory systolic blood pressure(SBP)Time frame: From enrollment to the end of treatment at 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.